


# IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I), ~~their analogs, their derivatives, their tautomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and their pharmaceutically acceptable compositions,~~ wherein G represents one of A, B, C, ~~[[D,]]~~ E, or F as described below:



$R_1$  represents hydrogen, substituted or unsubstituted groups selected the group consisting of from alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups;  $R_2$  represents alkyl, aralkyl, alkoxy or -NHR where R represents hydrogen or a lower alkyl group which may be suitably substituted;  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or a substituted or unsubstituted group selected from the group consisting of alkyl which may be linear or branched, alkenyl, cycloalkyl, alkoxy, cycloalkoxy, cycloalkoxyalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, and aralkoxycarbonyl groups; ~~when G represents heterocycle "D", then~~

~~at least one of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> is not hydrogen~~; R<sub>3</sub> represents a substituted or unsubstituted alkyl, or a substituted or unsubstituted, single or fused group selected from the group consisting of aryl, aralkenyl, heteroaryl, and heterocyclic groups; R<sub>4</sub> and R<sub>5</sub> represent hydrogen atom, halogen atom, carboxy, or a substituted or unsubstituted group selected from the group consisting of linear or branched alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, and phenyl groups; Y represents O or S; and W represents O or S.

2. (currently amended) The compound as claimed in claim 1, wherein the substituents on R<sub>3</sub> and R<sub>4</sub> ~~represent a~~ are selected from cyano, nitro, halo, carboxyl, ~~hydrazino, azido, formyl, amino, thio, hydroxy, ONO<sub>2</sub>, alkyl-ONO<sub>2</sub> or substituted or unsubstituted group groups~~ selected from the group consisting of alkyl which may be linear or branched, perhaloalkyl, alkoxy, ~~hydrazinoalkyl, alkylhydrazide, acyl, acyloxy, oxo, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfoximinyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aralkoxycarbonyl, alkoxycarbonylalkyl, amidino, carbexamidoalkyl, acylamino, cyanoamidino, cyanoalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-alkylamino, N,N-dialkylamino, N-arylamine, N-aralkylamine, N-alkyl-N-aralkylamine, N-alkyl-N-arylamine, N-alkylaminealkyl, N,N-dialkylaminealkyl, N-arylaminealkyl, N-aralkylaminealkyl, N-alkyl-N-aralkylaminealkyl, N-alkyl-N-arylaminealkyl, arylthio, aralkylthio, N-alkylaminesulfonyl, N-arylaminesulfonyl, arylsulfonyl, N,N-dialkylaminesulfonyl, N-alkyl-N-arylaminesulfonyl, alkoxycarbonyl, aminocarbonyl, or cycloalkyl, ~~heterocyclic, heterocyclicalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, and sulfamyl group.~~~~

3. (previously presented) The compound as claimed in claim 1, wherein the substituents on X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> represent a cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy or substituted or unsubstituted group selected from the group

consisting of alkyl which may be linear or branched, alkoxy, alkoxycarbonyl, acyl, acylamino, acyloxy, hydrazinoalkyl, alkylhydrazido, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, alkoxycarbonyl, and amidino groups.

4. (previously presented) The compound as claimed in claim 1, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or nitric acid.

5. (previously presented) A pharmaceutical composition comprising one or more compounds as claimed in claim 1 or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier, diluent, excipient, or solvate.

6. (currently amended) The pharmaceutical composition as claimed in claim 1, in the form of a tablet, capsule, powder, granule, syrup, solution, or suspension.

7. (previously presented) A pharmaceutical composition which comprises a pharmaceutically-acceptable salt as claimed in claim 4 and a pharmaceutically-acceptable carrier, diluent, excipient, or solvate.

8. (previously presented) The pharmaceutical composition as claimed in claim 7, in the form of a tablet, capsule, powder, granule, syrup, solution, or suspension.

9. (currently amended) A method of treating inflammation or pain ~~an inflammation-associated disorder~~ in a subject, said method comprising treating the subject having or

susceptible to such disorder with a therapeutically-effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

10. (previously presented) The method as claimed in claim 9, wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. (currently amended) A method of treating inflammation or ~~pain-an inflammation-associated disorder~~ in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a pharmaceutically-acceptable salt as claimed in claim 4.

12. (previously presented) The method as claimed in claim 11, wherein the pharmaceutically-acceptable salt is administered orally, nasally, parenterally, topically, transdermally, or rectally.

13. (previously presented) The compound as claimed in claim 1 which is selected from the group consisting of:

5-(4-Fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Chlorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
1-(4-methylsulfoximinyphenyl)-5-(4-*n*-propoxyphenyl)- 3-trifluoromethyl-1H-pyrazole;  
5-(4-Ethoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Hydroxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Chloro-4-fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3,4-Difluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;

5-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Chloro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Bromo-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Methoxy-4-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
1-(2-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;  
1-(3-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methylsulfoximinylphenyl)-5-phenyl-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methylsulfoximinylphenyl)-5-(1-naphthyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Methoxyphenyl)-3-methyl-1-(4-methylsulfoximinylphenyl)-1H-pyrazole;  
1-(4-Methylsulfoximinylphenyl)-5-(4-nitrophenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3,5-Difluoro-4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(3-Hydroxy-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole-3-carboxylic acid;  
3-(Hydroxymethyl)-5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole;  
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazol-3-ylmethylhydrogen sulphate;  
5-{4-(2-Hydroxy-ethoxy)phenyl}-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;

1-(4-Methylsulfoximinyphenyl)-5-(4-pyridyl)-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methylsulfoximinyphenyl)-5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methylsulfoximinyphenyl)-5-(2-pyridyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Isopropoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methylsulfoximinyphenyl)-5-(2-thiophenyl)-3-trifluoromethyl-1H-pyrazole;  
5-(4-Methylsulfoxyminyphenyl)-1-phenyl-3-trifluoromethyl-1H-pyrazole;  
1-(4-Methoxyphenyl)-5-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;  
5-Ethyl-4-(4-methylsulfoximinyphenyl)-3-phenyl-isoxazole;  
5-Methoxymethyl-4-(4-methylsulfoximinyphenyl)-3-phenyl-isoxazole;  
3-(4-Fluorophenyl)-5-methyl-4-(4-methylsulfoximinyphenyl)-isoxazole;  
3-(4-Chlorophenyl)-5-methyl-4-(4-methylsulfoximinyphenyl)-isoxazole;  
3-Ethyl-4-(4-methylsulfoximinyphenyl)-5-phenyl-isoxazole;  
5-Chloro-4-(4-methylsulfoximinyphenyl)-3-phenyl-isoxazole;  
5-Methyl-4-(4-methylsulfoximinyphenyl)-3-phenyl-isoxazole;  
3-(4-Methoxyphenyl)-5-methyl-4-(4-methylsulfoximinyphenyl)-isoxazole;  
3-(3,4-Dichlorophenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-(4-Chlorophenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-Phenyl-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-(3,4-Dimethoxyphenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-(4-Methoxyphenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
3-(4-Methylphenyl)-4-(3-fluoro-4-methylsulfoximinyphenyl)-5H-furan-2-one;  
5-Chloro-3-(4-methylsulfoximinyphenyl)-6'-methyl-[2,3']bipyridinyl;  
5-Chloro-3-(4-methylsulfoximinyphenyl)-[2,3']bipyridinyl;  
3-(3-Fluorophenyl)-4-(4-methylsulfoximinyphenyl)-3H-thiazol-2-one;  
3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinyphenyl)-3H-oxazol-2-one;  
3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinyphenyl)-3H-thiazol-2-one;  
3-(2-Fluorophenyl)-4-(4-methylsulfoximinyphenyl)-3H-oxazol-2-one;  
3-(4-Bromophenyl)-4-(4-methylsulfoximinyphenyl)-3H-oxazol-2-one;

4-(4-Methylsulfoximinylphenyl)-3-phenyl-3H-oxazol-2-one;  
3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;  
3-(3,4-Dichlorophenyl)-4-[4-(N-acetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;  
3-(3,4-Dichlorophenyl)-4-[4-(N-methylsulfonyl)methylsulfoximinyl-phenyl]-3H-oxazol-2-one;  
3-(3,4-Dichlorophenyl)-4-[4-{N-(4-methylphenyl)sulfonyl}-methylsulfoximinyl-phenyl]-3H-oxazol-2-one; and  
pharmaceutically-acceptable salts thereof.

14. (previously presented) The compound as claimed in claim 13, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or nitric acid.


15. (previously presented) A pharmaceutical composition, which comprises a compound or pharmaceutically-acceptable salt thereof as claimed in claim 13, and a pharmaceutically acceptable carrier, diluent, excipient, or solvate.

16. (previously presented) The pharmaceutical composition as claimed in claim 15, in the form of a tablet, capsule, powder, granules, syrup, solution, or suspension.

17. (currently amended) A method of treating inflammation or pain ~~an inflammation-associated disorder~~ in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in claim 13.


Claim 18 (canceled)

19. (previously presented) A process for preparing a compound of formula (I),



(I)

wherein G represents one of A, B, C, D, E, or F as described below:




R<sub>1</sub> represents hydrogen, substituted or unsubstituted groups selected from the group consisting of alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups; R<sub>2</sub> represents alkyl, aralkyl, or -NHR or -OR where R represents hydrogen or a lower alkyl group which may be suitably substituted; X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or a substituted or unsubstituted group selected from the group consisting of alkyl which may be linear or branched, alkenyl, oximealkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, and




aralkoxycarbonyl groups; when G represents heterocycle "D", then at least one of  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  is not hydrogen;  $R_3$  represents a substituted or unsubstituted alkyl, or a substituted or unsubstituted, single or fused group selected from the group consisting of aryl, aralkenyl, heteroaryl, and heterocyclic groups;  $R_4$  and  $R_5$  represent hydrogen atom, halogen atom, carboxy, or a substituted or unsubstituted group selected from the group consisting of linear or branched alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, and phenyl groups; Y represents O or S; and W represents O or S;

said process comprising: (a) oxidizing a compound of formula (P) to produce a compound of formula (Q) and (b) iminating the compound of formula (Q) to produce a compound of formula (I)




20. (previously presented) The process as claimed in claim 19 further comprising converting the compound of formula (I) to its pharmaceutically-acceptable salt




21. (currently amended) A process for preparing a compound of general formula (P) as defined in claim 19, said process comprising:

- i. reacting a haloketone of formula (II) with a compound of formula (III) to obtain a mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier;

- ii. converting an oxime of formula (VII) to a mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier;

- iii. reacting a hydrazine of formula (XI) with a 1,3-diketone of formula (XII) to form a mercapto compound of formula (P),




where G represents




~~and all other symbols are as defined earlier;~~

- iv. reacting a compound of formula (XVII) with a compound of formula (XVIII) to form a mercapto compound of formula (P),




where G represents



~~and all other symbols are as defined earlier; or~~

- v. reacting a compound of formula (XXI) with a compound of formula (XXII) to form a mercapto compound of formula (P),



where G represents



and all other symbols are as defined earlier.